1. DOP59 Evaluation of the efficacy of tofacitinib as maintenance therapy in patients with Ulcerative Colitis stratified by OCTAVE Sustain baseline endoscopic subscore. (27th May 2021) Authors: Lee, S D; Allegretti, J R; Steinwurz, F; Connelly, S B; Lawendy, N; Paulissen, J; Gecse, K B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S094 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study. (15th January 2020) Authors: Danese, S; Klopocka, M; Scherl, E J; Romatowski, J; Allegretti, J R; Peeva, E; Vincent, M S; Schoenbeck, U; Xi, L; Ye, Z; Hassan-Zahraee, M; Rath, N; Li, G; Neelakantan, S; Banfield, C; Lepsy, C; Chandra, D; Hung, K E Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P378 Rectal bleeding and stool frequency improvement with tofacitinib dose escalation to, 10 mg BID in patients with Ulcerative Colitis following loss of response on tofacitinib, 5 mg BID maintenance therapy: Results from OCTAVE Open. (21st January 2022) Authors: Allegretti, J R; Gecse, K B; Chiorean, M V; Argollo, M; Guo, X; Lawendy, N; Su, C; Mundayat, R; Paulissen, J; Salese, L; Irving, P M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i380 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study. (15th January 2020) Authors: Hassan-Zahraee, M; Ye, Z; Xi, L; Baniecki, M L; Li, X; Farin, W; Tibaldi, L; Allegretti, J R; Romatowski, J; Scherl, E J; Klopocka, M; Hyde, C; Danese, S; Longman, R; Hung, K E Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P477 Rectal bleeding and stool frequency improvement with tofacitinib retreatment in patients with Ulcerative Colitis after treatment interruption: Results from OCTAVE Open. (21st January 2022) Authors: Allegretti, J R; Gecse, K B; Chiorean, M V; Argollo, M; Guo, X; Lawendy, N; Su, C; Mundayat, R; Paulissen, J; Salese, L; Irving, P M Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P630 Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies. (30th January 2023) Authors: Schreiber, S W; Lim, A; Lacerda, A P; Allegretti, J R; Watanabe, K; Lukin, D; Dubenco, E; Ford, S; Oomen, J; Zhou, Q; Liu, J; Louis, E Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i759 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗